Miridesap is primarily utilized in the field of medical research, particularly in studies related to neurodegenerative diseases. It has been investigated for its potential role in reducing the levels of transthyretin (TTR) in the bloodstream. TTR is a protein that, when misfolded, can lead to amyloidosis, a condition where amyloid deposits accumulate in tissues and organs, causing damage. By lowering TTR levels, Miridesap may help in managing or preventing the progression of diseases such as familial amyloid polyneuropathy (FAP) and familial amyloid cardiomyopathy (FAC). Researchers are exploring its efficacy and safety as a therapeutic agent, aiming to provide a treatment option for patients suffering from these debilitating conditions.